Drugs Used in Parasomnia.
Study Goal
The researchers aimed to evaluate the pharmacologic treatment options for disorders of arousal (DOA) and rapid eye movement sleep behavior disorder, including the use of melatonin.
Results Summary
The study found that melatonin is one of the most commonly used drugs for rapid eye movement sleep behavior disorder, suggesting its symptomatic efficacy, though no specific outcomes or statistical results were detailed.
Population
Patients with parasomnia, specifically disorders of arousal (DOA) and rapid eye movement sleep behavior disorder.
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
benzodiazepines | no change | pharmacologic treatment of DOA | patients with DOA | - | most commonly used | #1 |
antidepressants | no change | pharmacologic treatment of DOA | patients with DOA | - | most commonly used | #2 |
clonazepam | no change | pharmacologic treatment of rapid eye movement sleep behavior disorder | patients with rapid eye movement sleep behavior disorder | - | most commonly used | #3 |
melatonin | no change | pharmacologic treatment of rapid eye movement sleep behavior disorder | patients with rapid eye movement sleep behavior disorder | - | most commonly used | #4 |
Patient education and behavioral management represent the first treatment approaches to the patient with parasomnia, especially in case of disorders of arousal (DOA). A pharmacologic treatment of DOA may be useful when episodes are frequent and persist despite resolution of predisposing factors, are associated with a high risk of injury, or cause significant impairment, such as excessive sleepiness. Approved drugs for DOA are still lacking. The most commonly used medications are benzodiazepines and antidepressants. The pharmacologic treatment of rapid eye movement sleep behavior disorder is symptomatic, and the most commonly used drugs are clonazepam and melatonin.